欧林生物9月24日大宗交易平台出现一笔成交，成交量16.00万股，成交金额358.56万元，大宗交易成交 价为22.41元，相对今日收盘价折价16.32%。该笔交易的买方营业部为机构专用，卖方营业部为广发证 券股份有限公司成都麓山大道证券营业部。 进一步统计，近3个月内该股累计发生8笔大宗交易，合计成交金额为2976.67万元。 据天眼查APP显示，成都欧林生物科技股份有限公司成立于2009年12月11日。注册资本40593.36万人民 币。（数据宝） 9月24日欧林生物大宗交易一览 | 成交量 | 成交金额 | 成交价格 | 相对当日收盘折溢 | 买方营 | 卖方营业部 | | --- | --- | --- | --- | --- | --- | | （万股） | （万元） | （元） | 价（%） | 业部 | | | 16.00 | 358.56 | 22.41 | -16.32 | 机构专 | 广发证券股份有限公司成都麓山 | | | | | | 用 | 大道证券营业部 | 注：本文系新闻报道，不构成投资建议，股市有风险，投资需谨慎。 （文章来源：证券时报网） 证券时报·数据宝统计显示，欧林生物今日 ...

每经记者｜陈星 每经编辑｜张海妮 9月23日，欧林生物（688319.SH，股价26.78元，市值108.71亿元）公告，正在筹划发行境外股份（H 股）并申请在香港联合交易所有限公司挂牌上市事宜。截至目前，公司正在与相关中介机构就本次H股 上市的相关工作进行商讨，关于本次H股上市的细节尚未确定。 此次定增计划始于2024年4月，公司于去年6月公布了定增预案。最初的定增预案显示，此次的发行对象 为11名投资者，发行价格为13.71元/股（定价基准日前20日股价均价的80%），根据发行的竞价结果， 发行对象拟认购金额合计为1.75亿元，募集资金拟用于现有疫苗研发生产基地技术的改造项目。 而在今年8月更新的定增预案中，欧林生物将募集资金总额下调到1.25亿元。但最终该定增未能落地。9 月1日，欧林生物公告，鉴于当前市场情况，结合公司实际情况及发展规划等诸多因素，公司决定终止 以简易程序向特定对象发行股票事项，并撤回相关申请文件。但公司表示，原计划投入募集资金建设 的"疫苗研发生产基地技术改造项目"仍将按计划有序推进。 公司曾表示将寻求研发投入和经营现金流之间的平衡 从欧林生物上半年业绩来看，其在报告期内扭亏为盈，但 ...

Core Viewpoint - Chengdu Olin Biological Technology Co., Ltd. is planning to issue H-shares and apply for listing on the Hong Kong Stock Exchange to enhance its international strategy, increase its global visibility, and optimize its capital structure [1][2]. Group 1 - The company is currently discussing the details of the H-share listing with relevant intermediaries, and specific details have not yet been finalized [2]. - The H-share listing process will require approval from the company's board and shareholders, as well as regulatory approvals from the China Securities Regulatory Commission, the Hong Kong Stock Exchange, and the Securities and Futures Commission of Hong Kong [2]. - The company will fulfill its information disclosure obligations in accordance with relevant laws and regulations as the H-share listing progresses [2].

Group 1: Company Announcements - Ganli Pharmaceutical signed a technology transfer and supply agreement with FZ and BIOMM, with a total supply framework agreement amount expected to be no less than 3 billion RMB [1] - Upwind New Materials completed the transfer of 121 million shares, changing its controlling shareholder to Zhiyuan Hengyue, associated with Zhiyuan Robotics [2] - Poly Developments plans to publicly issue corporate bonds not exceeding 15 billion RMB for various purposes including debt repayment and project construction [3] Group 2: Shareholder Actions - Lenovo Holdings reduced its stake in Lakala by 8.0781 million shares, decreasing its ownership from 25.00% to 23.97% [4] - Fenghuo Communication plans to repurchase shares with a budget between 75 million and 150 million RMB, with a maximum repurchase price of 40.53 RMB per share [5] - Hualing Cable intends to acquire control of San Bamboo Intelligent for no more than 270 million RMB to enhance its capabilities in robotics and high-frequency transmission [6] Group 3: Market Developments - Guiguang Network clarified that rumors regarding major collaborations with Huawei Cloud and restructuring with state-owned enterprises are untrue [7] - Dongshan Precision is planning to issue H-shares and list on the Hong Kong Stock Exchange to enhance its international presence [8] - Wolong Nuclear Materials' subsidiary plans to invest up to 1 billion RMB in a new materials project in Suzhou [9] Group 4: Other Corporate Activities - Chao Xun Communication's management completed their share reduction plan, with specific shares sold by board members [10] - Various companies are involved in significant project bids and collaborations, including China Electric Research and others [15]

★ 宏观动态 ★ 经合组织预测2025年全球经济增速为3.2%，2026年将放缓至2.9% 经济合作与发展组织（经合组织）23日发布中期经济展望报告，预计2025年全球经济增速为3.2%，较今年6月 预测值上调0.3个百分点；2026年全球经济增速将放缓至2.9%，与6月预测值相同。 陕西省省长赵刚：中欧班列西安集结中心已开通国际干线18条、覆盖亚欧大陆全境 陕西省省长赵刚今日在2025欧亚经济论坛上表示，中欧班列西安集结中心已开通国际干线18条、覆盖亚欧大陆 全境，核心指标稳居全国第一，上半年开行3055列、同比增长28.8%。西安国际航空枢纽，已开通国际客运航 线60条、全货运航线16条，上半年国际航班客运量、货运量分别增长71%和124.8%。我们持续提升枢纽的承载 力、辐射力，推动港产港贸港城融合发展，引导外向度高的适铁、临空产业集聚发展。如今，中欧班列满载着 汽车、光伏、家电等"陕西制造"横贯欧亚、走向世界。 工信部：组合驾驶辅助系统乘用车新车市场渗透率超60% 香港交易所今天宣布与广州碳排放权交易中心有限公司，深圳绿色交易所， 澳门国际碳排放权交易所签署合 作备忘录，携手推动粤港澳大湾区碳市场及绿 ...

Core Viewpoint - The company, Olin Bio, is planning to issue overseas shares (H-shares) and apply for listing on the Hong Kong Stock Exchange to enhance its international presence and optimize its capital structure [2] Group 1: Company Strategy - The company aims to deepen its international strategic layout and increase its global recognition and influence [2] - The initiative is part of a broader effort to strengthen the company's overall competitive capabilities [2] Group 2: Listing Process - Currently, the company is in discussions with relevant intermediaries regarding the H-share listing [2] - Specific details about the H-share listing are yet to be determined [2] - The listing process will require approval from the company's board and shareholders, as well as regulatory approvals from the China Securities Regulatory Commission, Hong Kong Stock Exchange, and the Securities and Futures Commission of Hong Kong [2]

Core Viewpoint - The company, Olin Bio (688319.SH), is planning to issue overseas shares (H-shares) and apply for listing on the Hong Kong Stock Exchange to enhance its international strategy, increase global recognition, and optimize its capital structure [1] Group 1 - The company aims to deepen its international strategic layout [1] - The initiative is intended to enhance the company's international visibility and influence [1] - The move is part of efforts to strengthen the company's overall competitive strength [1]

证券代码：688319 证券简称：欧林生物 公告编号：2025-048 成都欧林生物科技股份有限公司 关于筹划发行 H 股股票并在香港联合交易所有限公司 上市的提示性公告 本公司董事会及全体董事保证本公告内容不存在任何虚假记载、误导性陈述 或者重大遗漏，并对其内容的真实性、准确性和完整性依法承担法律责任。 成都欧林生物科技股份有限公司(以下简称"公司")为深化公司国际化战略 布局，提升国际知名度与影响力，并进一步优化资本结构，增强综合竞争实力， 正在筹划发行境外股份（H 股）并申请在香港联合交易所有限公司（以下简称"香 港联交所"）挂牌上市事宜（以下简称"本次 H 股上市"）。 截至目前，公司正与相关中介机构就本次 H 股上市的相关工作进行商讨，关 于本次 H 股上市的细节尚未确定。根据《中华人民共和国公司法》《中华人民共 和国证券法》《上海证券交易所科创板股票上市规则》《境内企业境外发行证券 和上市管理试行办法》《香港联合交易所有限公司证券上市规则》等相关法律法 规和规范性文件的要求，待确定具体方案后，本次 H 股上市工作尚需提交公司董 事会和股东会审议，并需取得中国证券监督管理委员会、香港联交所和香港证券 ...

Group 1 - The company, Olin Bio (688319.SH), is planning to issue overseas shares (H-shares) and apply for listing on the Hong Kong Stock Exchange to enhance its international presence and influence [1] - This initiative is part of the company's strategy to deepen its internationalization efforts and optimize its capital structure [1] - The goal of this move is to strengthen the company's overall competitiveness in the market [1]

Group 1 - The company, Olin Bio (688319.SH), is planning to issue overseas shares (H-shares) and apply for listing on the Hong Kong Stock Exchange to enhance its international presence and influence [1] - This initiative is part of the company's strategy to deepen its internationalization and optimize its capital structure [1] - The goal is to strengthen the company's overall competitiveness in the market [1]